文献速递产科母胎医学

全身多剂量甲氨蝶呤保守治疗剖宫产瘢痕妊娠:治疗失败预测因素与生殖结局

Conservative management of Caesarean scar pregnancies with systemic multidose methotrexate: predictors of treatment failure and reproductive outcomes.
PubMed 文献 · Reprod Biomed Online · 2019-05-24

回顾性队列纳入36例剖宫产瘢痕妊娠患者,按保守治疗意图接受全身甲氨蝶呤(MTX)治疗,29/36(80.6%)仅全身注射MTX,其余19.4%联合全身与局部(囊内)MTX。5例(13.9%)需侵入性干预(失败组)。失败组既往剖宫产次数更高(中位数4 vs 2,P=0.002),既往剖宫产次数是转手术的唯一独立相关因素(OR 2.02,95%CI 1.03-3.94)。结论认为全身MTX治疗安全有效,后续生殖结局良好,转手术率低。

要点

  • 36例剖宫产瘢痕妊娠中29/36(80.6%)仅用全身MTX,19.4%联合局部MTX。
  • 5例(13.9%)需侵入性干预,失败组既往剖宫产次数中位数4 vs 成功组2(P=0.002)。
  • 既往剖宫产次数是转手术的唯一独立相关因素(OR 2.02,95%CI 1.03-3.94)。

核心结论

  • 全身MTX治疗是剖宫产瘢痕妊娠的安全有效策略,后续生殖结局良好且转手术率低。

研究设计与样本

  • 回顾性队列研究,纳入所有诊断为剖宫产瘢痕妊娠并按保守治疗意图接受全身甲氨蝶呤(MTX)治疗的患者,共36例。

主要发现

  • 29/36(80.6%)仅接受全身MTX注射,其余19.4%接受全身与局部(囊内)MTX联合治疗。
  • 5例(13.9%)需要侵入性干预(失败组)。
  • MTX治疗成功者中位消退时间为22天(四分位距13-37天)。
  • 转为手术治疗者既往剖宫产次数更高(中位数4 vs 2,P=0.002)。
  • logistic回归中,既往剖宫产次数是转手术管理的唯一独立相关因素(OR 2.02,95%CI 1.03-3.94)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Caesarean scar pregnancy (CSP) is an increasing concern in modern obstetrics. Early diagnosis and management are of utmost importance. The optimal management approach for CSP is not well established, with various treatment modalities reported. The role of conservative management of CSP has been previously reported, with conflicting results. This study aimed to further evaluate its role and better delineate the subsequent reproductive outcomes. DESIGN: A retrospective cohort study including all patients diagnosed with a CSP and treated by intention of conservative management with systemic methotrexate (MTX). Maternal and gestation characteristics were compared between treatment success and failure groups. RESULTS: Thirty-six cases of CSP were encountered. Overall, 29/36 (80.6%) were treated by systemic injection of MTX while the other 19.4% had combined systemic and local (i.e. intra-sac) MTX treatment. Invasive intervention was needed in five (13.9%) cases (failure group). Among those successfully treated with MTX, the median time to resolution was 22 (interquartile range 13-37) days. Cases who were converted to surgical treatment had a higher number of previous Caesarean deliveries (median 4 versus 2, P = 0.002). In logistic regression modelling, the number of previous Caesarean deliveries was the only factor independently associated with conversion to surgical management (odds ratio 2.02, 95% confidence interval 1.03-3.94). The majority of future pregnancies ended at term pregnancy with only one preterm delivery due to severe intrauterine growth restriction. CONCLUSIONS: Systemic MTX therapy is a safe and effective strategy for the treatment of CSP, with favourable subsequent reproductive results and a low conversion rate to surgical management.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Levin G, Zigron R, Dior UP, et al. Conservative management of Caesarean scar pregnancies with systemic multidose methotrexate: predictors of treatment failure and reproductive outcomes. Reprod Biomed Online. 2019. PMID: 31530445. doi:10.1016/j.rbmo.2019.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。